Supriya Lifescience Ltd

Supriya Lifescience USFDA Inspection Outcome 🏭✅

- USFDA inspection conducted from February 2 to 6, 2026.

- Only one minor observation noted on Form 483.

- Observation addressed and resolved by the company.

- Received EIR with 'Voluntary Action Indicated' status, indicating successful completion.

- Company reaffirms commitment to full cGMP compliance across all facilities.